Analysis of long-term survivors after platinum containing chemotherapy in advanced non-small cell lung cancer

Anticancer Research

Volumn 18, Issue 2 B, 1998, Pages 1295-1298

  Satoh, Hiroaki ^a   Ishikawa, Hiroichi ^b   Yamashita, Yuko T ^a   Naito, Takashi ^b   Takahashi, Hideto ^a   Kamma, Hiroshi ^a   Ohtsuka, Morio ^a   Hasegawa, Shizuo ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b TSUKUBA MEDICAL CENTER HOSPITAL   (Japan)

Author keywords

Chemotherapy; Long term survivor; Non small cell lung cancer; Prognostic factor

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; FLUOROURACIL; IFOSFAMIDE; PLATINUM DERIVATIVE; VINDESINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; VINDESINE;

EID: 0031859135     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Minna JD, Pass H, Glastein E, Ihde DC: Cancer of the lung. In: principles and practice of oncology, DeVita TV, Hellman S, Rosenberg SA, eds, Philadelphia, Lippincott, 591-705, 1989.
2. Tominaga S: Future prediction of cancer deaths in Japan. Jpn J Cancer Chemother 16: 101-111, 1989.
3. Veronesi A, Magri MD, Tirelli U: Chemotherapy of advanced non-small cell lung cancer with cyclophosphamide, adriamycin, methotrexate and procarbazine versus cisplatin and etoposide: a randomized study. Am J Clin Oncol 11: 566-571, 1988.
4. Luedke DW, Einhorn L, Omura GA, Sarma PR, Bartolucci AA, Birch R, Greco FA: Randomized comparison of two combination regimens versus minimal chemotherapy in non-small cell lung cancer. A Southeastern Cancer Study Group Trial. J Clin Oncol 8: 886-891, 1990.
5. Ellis PA, Smith IE, Hardy JR, Nicolson MC, Tolbot DC, Ashley SE, Priest K: Symptom relief with MPV(mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 71: 366-370, 1995.
6. Simes RJ: Risk-benefit relationships in cancer clinical trials. J Clin Oncol 3: 462-472, 1985.
7. Ruckdeschel JC, Finkelstein DM, Ettinger DS. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 4: 1422, 1986.
8. Cellerino R, Tummarello D, Piga A: Chemotherapy or not in advanced non-small cell lung cancer? Lung Cancer 6: 99-109, 1990.
9. De Angelis G, Cipri A, Flore F, Munno R: UICC: TNM classification of malignant tumor. 4th ed. Geneva, Switzerland: International Union Against Cancer, 1987.
10. UICC: TNM supplement 1993 A commentary on uniform use. Berlin, Springer-Verlag, 1993.
11. World Health Organization. Histological Typing of the Lung Tumors. Am J Clin Pathol 77: 123-36, 1982.
12. Satoh H, Yano H, Ishikawa H, Hasegawa S: Disease extent and response to chemotherapy in non-small cell lung cancer. Acta Oncol 35: 106-107, 1996.
13. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations J Am Stat Assoc 53: 457-481, 1958.
14. Cox DR. Regression models and life tables. J R Statist Soc B 34: 187-220, 1972.
15. Finkelstein DM, Ettinger DS, Ruckdeschel JC: Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 4: 702-709, 1986.
16. Albain KS, Crowley JJ, Leblanc M, Livingston RB: Survival determinations in extensive stage non-small cell lung cancer: the Southwest Oncology Group Experience. J Clin Oncol 9: 1618-1626, 1991.
17. Sculier JP, Paesmans M, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Schmerber J, Giner V: Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer. European Lung Cancer Working Party. Eur J Cancer 30A: 1342-1347, 1994.
18. Kojima A, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Oshita F, Miya T, Okamoto H, Kondo H, Tajima K, Makuch RW, Saijo N: Analysis of three-year survivors among patients with advanced inoperable non-small cell lung cancer. Jpn J Clin Oncol 21: 276-281, 1991.
19. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AM: Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer. Report of a Canadian Multicenter Trial. J Clin Oncol 6: 633-641, 1988.
20. Cellerino R, Tummarello D, Porfiri E, Guidi F, Isidori P, Raspugli M, Biscottini B, Fatati G: Non-small cell lung cancer. A prospective randomized trial with alternating chemotherapy CEP/MEC versus no treatment. Eur J Cancer Clin Oncol 24: 1839-1843, 1988.
21. Williams CJ, Woods R, Levi J, Page J: Chemotherapy for non-small cell lung cancer. A randomized trial of cisplatin/vindesine versus no chemotherapy. Semin Oncol 15(suppl 7): 58-61, 1988.
22. Ganz PA, Figlin RA, Haskell CM, La-Sato N, Siau J: Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Cancer 63: 1271-1278, 1989.
23. Raasa S, Lund E, Thorud E, Hatlevoll R, Host H: Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer 67: 2443-2447, 1991.
24. Ihde DC: Chemotherapy of lung cancer. N Engl J Med 327: 1434-1441, 1992.
25. Donnadieu N, Paesmans M, Sculier JP: Chemotherapy of non small cell lung cancer according to disease extent: a meta analysis of the literature. Lung Cancer 7: 243-252, 1991 .
26. Vokes EE, Bitran JD, Vogelzang NJ: Chemotherapy for non-small cell lung cancer: the continuing challenge. Chest 99: 1326-1328, 1991.
27. Sculier JP, Klastersky J. Progress in chemotherapy of non-small cell lung cancer. Eur J Cancer Clin Oncol 20: 1329-1333, 1984.
28. Shikai T, Eguchi K, Sasaki Y, Tamora T, Ohe Y, Kojima A, Oshita F, Miya T, Okamoto H, Iemura K, Saijo N: A prognostic factor risk index in advanced non-small-cell lung cancer treated with cisplatincontaining combination chemotherapy. Cancer Chemother Pharmacol 30: 1-6, 1992.
29. Paesmans M, Schlier JP, Libert P, Bureau G, Dabouis G, Thriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P, Klastersky J: Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. J Clin Oncol 13: 1221-1230, 1995.
30. Murren JR, Buzaid AC, Hait WN: Critical analysis of neoadjuvant therapy for stage IIIa non-small cell lung cancer. Am Rev Respir Dis 143: 889-894, 1991.
31. Van Raemdonck DE, Schneider A, Ginsberg RJ: Surgical treatment for higher stage non-small cell lung cancer. Ann Thrac Surg 54: 999-1013, 1992.
32. Hazuka MB, Bunn PA Jr: Controversies in the nonsurgical treatment of stage III non-small cell lung cancer. Am Rev Respir Dis 145: 967-977, 1992.
33. Belani CP, Aisner J: Combined-modality therapies for non-small cell lung cancer. Ann Oncol 3(suppl 3): S3-S10, 1992.